Answers are grounded in this paper and cite their sources.
The Human papillomavirus (HPV) vaccine was the first vaccine developed to protect against a sexually transmitted disease. Throughout the past decade, bivalent (2vHPV), quadrivalent (4vHPV), and nonvalent (9vHPV) vaccines have been widely distributed throughout the world. In this narrative review, we will discuss the pathologic and immunologic efficacy of the different HPV vaccine valencies, specifically focusing on their ability to prevent genital warts and malignant neoplasms. Although vaccine efficacy and safety remain high across all valencies, there is growing vaccine hesitancy towards the HPV vaccines which is detrimental towards the establishment of herd immunity. We will examine the challenges associated with tracking and administering a multi-dose regimen in both developing and developed nations and discuss new findings that suggest vaccination with a single dose against HPV confers significant immunity towards the virus. We conclude that a one dose HPV vaccine solution would be a worthwhile investment, and instrumental in achieving herd immunity against HPV in both developed and developing nations.
No takes yet. Share an insight, caveat, or question.
Abdullah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: